- Home
- CLDX vs CLVT Comparison
CLDX vs CLVT Comparison
Compare CLDX & CLVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CLDX | CLVT |
|---|---|---|
| Founded | N/A | 2016 |
| Country | United States | United Kingdom |
| Employees | N/A | 12000 |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | EDP Services |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 1.7B |
| IPO Year | 1995 | N/A |
Fundamental Metrics
Financial Performance| Metric | CLDX | CLVT |
|---|---|---|
| Price | $33.29 | $2.81 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 10 | 7 |
| Target Price | ★ $46.60 | $3.22 |
| AVG Volume (30 Days) | 725.4K | ★ 4.8M |
| Earning Date | 05-04-2026 | 04-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $12,743,000.00 | N/A |
| Revenue This Year | $111.39 | N/A |
| Revenue Next Year | $235.85 | $2.12 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 87.78 | N/A |
| 52 Week Low | $18.20 | $1.66 |
| 52 Week High | $35.83 | $4.77 |
Technical Indicators
Market Signals| Indicator | CLDX | CLVT |
|---|---|---|
| Relative Strength Index (RSI) | 53.45 | 59.28 |
| Support Level | $28.30 | $2.29 |
| Resistance Level | $35.18 | $3.73 |
| Average True Range (ATR) | 1.32 | 0.19 |
| MACD | -0.14 | 0.02 |
| Stochastic Oscillator | 40.19 | 63.43 |
Price Performance
Historical ComparisonAbout CLDX Celldex Therapeutics Inc.
Celldex Therapeutics Inc is a biopharmaceutical firm focused on mast cell biology and the development of therapeutic antibodies. Its pipeline includes monoclonal and bispecific antibodies aimed at treating severe inflammatory, allergic, autoimmune, and other mast cell-mediated diseases. The company operates in a single operating and reportable segment in the business of development, manufacturing and commercialization of novel therapeutics for human health care.
About CLVT Clarivate Plc
Clarivate is a data, information, and software workflow solutions company serving customers primarily in academia, government, law, life sciences, and healthcare. The company was formerly part of Thomson Reuters before being sold to private equity as an independent company in 2016. In 2019, Clarivate went public on the New York Stock Exchange. Around half of the company's revenue is generated in the Americas, while Europe, Middle East, and Africa account for around a quarter.